Video

Weighing the Risks and Benefits of Colorectal Cancer Treatment During the COVID-19 Pandemic

Despite the impact that COVID-19 is having on cancer treatment schedules, one expert stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.

To comment on what he’s seeing in practice at the University of Colorado Cancer Center and in his work with the Colorectal Cancer Alliance, CURE® spoke with Dr. Christopher Lieu, who offered some tips on how patients with colorectal cancer can navigate the novel coronavirus crisis.

“What’s going on right now is completely unprecedented,” said Lieu. “We’re learning along with our patients more about the virus and how to combat it, and the impact of COVID-19 on our patients.”

In determining what’s best for each of his patients, Lieu explained that the conversations focus on risks of exposing patients to possible infection versus the benefits of treatment. But as he noted, “Cancer doesn’t care if there’s a pandemic or not. Cancer’s not going to stop just because we’re dealing with a pandemic and our patients understand that better than anybody.”

Despite the impact that COVID-19 is having on treatment schedules and the anxiety that self-imposed isolation can cause, Lieu stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.

“The real take-home message here is that even if your risk for developing COVID-19 is really low, by doing some of these things, not only are you protecting yourself and those that are close to you, but you really could be saving the life of someone you’ve never met before,” said Lieu.

“If you think about it that way, it provides a lot of motivation to do these things and do them right.”

Related Videos
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Related Content